// App-Quantinova.ai

58 : The Addition of Bevacizumab to Standard Therapy with R-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Is Associated with an Increased Rate of Cardiac Adverse Events: Final Analysis of Safety and Efficacy Outcomes From the Placebo-Controlled Phase 3 MAIN Study

Researchers

Presenter

  • Michael Pfreundshuh

Principal Investigators

  • B. Coiffier

  • Marek Trneny

  • Laurie H. Sehn

  • Eva Csinady

Medical Centers

  • Vseobecna Fakultni Nemocnice V Praze, Prague, Czech Republic

  • GINECO & Centre Hospitalier Lyon-Sud, Lyon, France

  • Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, British Columbia, Canada

  • Department of Medicine II, Saarland University Hospital, Homburg, Germany

  • Peter MacCallum Cancer Centre, East Melbourne, Australia

Locations

  • Czech Republic

  • Canada

  • Germany

  • Australia

  • France

Companies

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Congestive heart failure

  • Cardiotoxicity

  • B cell lymphomas

  • Heart muscle disease

  • Left ventricular dysfunction

  • Hypertension

  • Lymphomas

Biomarkers

  • B-lymphocyte antigen CD20

Drug/Treatment

  • Bevacizumab

  • Doxorubicin

Outcome

  • N/A

Study Design

  • randomized

  • double blind/blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved